Category Archives: Business and Investments

Latest From Business and Investments

JOBS Act: Rule 506 Goes Into Effect Today

DC in Fall

Since Congress passed the Jumpstart our Business Startups (JOBS) Act last spring, there have been 39 IPOs in the biotech industry – and counting!  Today, another provision from the JOBS Act takes effect that will further enhance biotech capital formation. Pursuant to rules mandated by the JOBS Act, companies are now able to use general solicitation to advertise to investors when conducting an offering under Rule 506 of SEC Regulation D.  Rule 506 is a Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: ,

BIO Investor Forum Company Snapshot: Opsona Therapeutics

opsona115x76

Opsona Therapeutics will be participating in the upcoming BIO Investor Forum, and will be giving a presentation on their work in the autoimmune/inflammatory diseases and oncology space (among other indications). To learn more about their company, please read one of our final company snapshots below. Company Snapshot What is your company’s lead product or technology? Opsona’s lead product OPN-305 is a fully humanized monoclonal IgG4 antibody targeting Toll-like-receptor-2 (TLR2), which is in clinical development as Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

BioCentury This Week: Death & Taxes – Startups Need Fixes

BioCenturyTV

Vitae CEO Jeff Hatfield, Ernst & Young Partner Christopher Ohmes, and GPB Scientific CEO Michael Grisham will be discussing proposed tax changes that could spur billions of dollars in investment and create hundreds of thousands of jobs on BioCentury This Week airing Sunday September, 15 at 8:30am EST on WUSA-9. Biotech startups face death before taxes and unless investors are willing to finance years of losses, technologies that could save and improve lives are left Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , ,

BIO Investor Forum Company Snapshot: Vaccinex

Vaccinex

Recently, the CEO of Prosensa provided their company’s perspective participating in last year’s BIO Investor Forum. Looking ahead at this year’s event, we spoke to the President & CEO of Vaccinex, Dr. Maurice Zauderer. They will be presenting in the regular private track, which features later-stage private companies. Read below to learn more about this biotech.   Company Snapshot What is your company’s lead product or technology? Vaccinex’s lead product, VX15, is an antibody to semaphorin Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

E&Y Study: 3 Tax Tweaks that Could Spur Job Growth

87881842

A new report from Ernst & Young illustrates the economic impact of three tax proposals intended to help small businesses spur innovative research and development. The report indicates that the three tax revisions, if enacted together, could drive up research and development investments by more than $20 billion and create an estimated 623,000 new jobs at new and small firms. The report outlines the potential impact of the three proposals, which include: The R&D partnership Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , ,